The release of the bromodomain ligand N,N-dimethylacetamide adds bioactivity to a resorbable guided bone regeneration membrane in a rabbit calvarial defect model

Abstract

N,N-Dimethylacetamide (DMA) is FDA approved as an excipient and is used as drug-delivery vehicle. Due to its amphipathic nature and diverse bioactivities, it appears to be a good combination of biodegradable poly-lactide-co-glycolide (PLGA)-based guided bone regeneration membranes. Here we show that the solvent DMA can be loaded to PLGA membranes by different regimes, leading to distinct release profiles, and enhancing the bone regeneration in vivo. Our results highlight the potential therapeutic benefits of DMA in guided bone regeneration procedures, in combination with biodegradable PLGA membranes.